Advertisement

Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer

Published:December 01, 2020DOI:https://doi.org/10.1016/j.jgo.2020.11.008

      Abstract

      Women with triple negative breast cancer (TNBC) have a high prevalence of BRCA1 mutations, and current clinical guidelines recommend genetic testing for patients with TNBC aged ≤60 years. However, studies supporting this recommendation have included few older women with TNBC.

      Methods

      Genetic testing results from women aged >60 years with TNBC enrolled in the Clinical Cancer Genomics Community Research Network (CCGCRN) registry were included in this analysis. Prevalence of breast cancer-associated pathogenic variants (PVs) was compared across age groups.

      Results

      We identified 151 women with TNBC aged >60 years (median 65 years; SD 5.3). Of these, 130 (86%) underwent genetic testing, and a breast cancer–associated PV was identified in 16 (12.3%; 95% CI 7–19): BRCA1 (n = 6), BRCA2 (n = 5), PALB2 (n = 2), ATM (n = 1) and RAD51C (n = 2). We found no differences in the proportion of patients with close blood relatives with breast (≤50 years) or ovarian cancer (any age) between PV carriers (37.5%) and non-carriers (34.2%) (p = 0.79). Among PV's carriers, the proportion of older women with a BRCA1 PV was lower when compared to younger women (37.5% vs 77.2%; p < 0.01).

      Conclusion

      Breast cancer-associated PVs were found in an important proportion of women aged >60 years with TNBC undergoing genetic testing, including greater representation of BRCA2. These results suggest that older women with TNBC should be offered genetic testing, and that their exclusion based on chronologic age alone may not be appropriate.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ferlay J.
        • Ervik M.
        • Lam F.
        • et al.
        Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer, global cancer.
        Observatory. 2018; (accessed [29 November 2020].)
        • Howlader N.
        • Altekruse S.F.
        • Li C.I.
        • et al.
        US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
        J Natl Cancer Inst. 2014; 106
        • Shimelis H.
        • LaDuca H.
        • Hu C.
        • et al.
        Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing.
        JNCI: J Nation Cancer Instit. 2018; 110: 855-862
        • Couch F.J.
        • Hart S.N.
        • Sharma P.
        • et al.
        Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
        J Clin Oncol. 2015; 33: 304-311
        • NCCN
        NCCN clinical practice guidelines in oncology. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic. Version 1.2020-December4, 2019.
        in: NCCN Clinical Practice Guidelines. 2019
        • Chavarri-Guerra Y.
        • Hendricks C.B.
        • Brown S.
        • et al.
        The burden of breast cancer predisposition variants across the age spectrum among 10 000 patients.
        J Am Geriatr Soc. 2019; 67: 884-888
        • Hahnen E.
        • Hauke J.
        • Engel C.
        • et al.
        Germline mutations in triple-negative breast cancer.
        Breast Care (Basel). 2017; 12: 15-19
        • Mavaddat N.
        • Barrowdale D.
        • Andrulis I.L.
        • et al.
        Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA).
        Cancer Epidemiol Biomark Prev. 2012; 21: 134-147
        • Buys S.S.
        • Sandbach J.F.
        • Gammon A.
        • et al.
        A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
        Cancer. 2017; 123: 1721-1730